Interferons in relapsing remitting multiple sclerosis.

Interferons in relapsing remitting multiple sclerosis.

Bibliográfalaš dieđut
Váldodahkki:	Goodin, D
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2003

Geahča maid

Interferons in relapsing remitting multiple sclerosis - Authors' reply
Dahkki: Filippini, G, et al.
Almmustuhtton: (2003)

Interferons in relapsing remitting multiple sclerosis - Authors' reply
Dahkki: Filippini, G, et al.
Almmustuhtton: (2003)

Interferons in relapsing remitting multiple sclerosis: a systematic review.
Dahkki: Filippini, G, et al.
Almmustuhtton: (2003)

Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
Dahkki: Làzaro Aurelio Vàzquez Gòmez, et al.
Almmustuhtton: (2022-10-01)

Thalamic neurodegeneration in relapsing-remitting multiple sclerosis.
Dahkki: Wylezinska, M, et al.
Almmustuhtton: (2003)

Thalamic neurodegeneration in relapsing: Remitting multiple sclerosis
Dahkki: Cifelli, A, et al.
Almmustuhtton: (2003)

Comorbidity in in patients with relapsing-remitting multiple sclerosis
Dahkki: O.V. Somilo, et al.
Almmustuhtton: (2024-10-01)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
Dahkki: Petkau, A, et al.
Almmustuhtton: (2004)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
Dahkki: Petkau, A, et al.
Almmustuhtton: (2004)

Cost-utility analysis of interferon beta-1a (Avonex and Cinnovex) for relapsing remitting multiple sclerosis
Dahkki: Rahil Sadat Shahtaheri, et al.
Almmustuhtton: (2018-06-01)

Experience with the long-term use of interferons β in the treatment of relapsing-remitting multiple sclerosis. Case report
Dahkki: Taras O. Simaniv, et al.
Almmustuhtton: (2024-12-01)

Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
Dahkki: Fernando Rodríguez-Jorge, et al.
Almmustuhtton: (2024-11-01)

Cerebellar information processing in relapsing-remitting multiple sclerosis (RRMS).
Dahkki: Lesage, E, et al.
Almmustuhtton: (2010)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
Dahkki: E. Lesage, et al.
Almmustuhtton: (2010-01-01)

Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines
Dahkki: Paty, D, et al.
Almmustuhtton: (1999)

Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
Dahkki: Fernando Rodríguez-Jorge, et al.
Almmustuhtton: (2024-12-01)

Prooxidant-antioxidant balance in relapsing-remitting multiple sclerosis patients
Dahkki: Samaneh Sabouri, et al.
Almmustuhtton: (2023-07-01)

The condition of the cardiovascular system in patients with relapsing-remitting multiple sclerosis
Dahkki: O. A. Traktirskaya, et al.
Almmustuhtton: (2019-03-01)

Efficacy and Safety of PEGylated Interferons for Relapsing-Remitting Multiple Sclerosis in Adult Patients: Results of Matching-Adjusted Indirect Comparison
Dahkki: Taras O. Simaniv, et al.
Almmustuhtton: (2024-04-01)

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Dahkki: Ebers, G, et al.
Almmustuhtton: (1998)

Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis.
Dahkki: Rozanna Meijboom, et al.
Almmustuhtton: (2023-01-01)

Are Sirtuins 1 and 2 Relevant Players in Relapsing–Remitting Multiple Sclerosis?
Dahkki: Justyna Chojdak-Łukasiewicz, et al.
Almmustuhtton: (2024-09-01)

Ocrelizumab alters the circulating metabolome in people with relapsing–remitting multiple sclerosis
Dahkki: Fatemeh Siavoshi, et al.
Almmustuhtton: (2024-09-01)

A review of treatment of relapsing-remitting type of multiple sclerosis (RRMS)
Dahkki: Arkadiusz Bydliński, et al.
Almmustuhtton: (2024-05-01)

Meta‐analysis of the use of Ofatumumab in the treatment of relapsing‐remitting multiple sclerosis
Dahkki: Peter Olujimi Odutola, et al.
Almmustuhtton: (2023-09-01)

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
Dahkki: Fatemeh Yavari, et al.
Almmustuhtton: (2021-03-01)

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Dahkki: Reder, A, et al.
Almmustuhtton: (2010)

Analysis of the experience with once-weekly intramuscular administration of interferon beta-1a in the Russian population of patients with relapsing-remitting multiple sclerosis
Dahkki: F. A. Khabirov, et al.
Almmustuhtton: (2024-08-01)

Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
Dahkki: Silvia Boullosa-Lale, et al.
Almmustuhtton: (2021-03-01)

Clinical features of cognitive dysfunction in patients with relapsing-remitting type of multiple sclerosis
Dahkki: O.S. Teslenko, et al.
Almmustuhtton: (2024-03-01)

In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
Dahkki: Fianne L. P. Sips, et al.
Almmustuhtton: (2022-11-01)

Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis
Dahkki: Masoud Ghiasian, et al.
Almmustuhtton: (2024-02-01)

Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability
Dahkki: S. Migliore, et al.
Almmustuhtton: (2017-01-01)

Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis
Dahkki: Ahmad, H, et al.
Almmustuhtton: (2018)

De novo relapsing-remitting multiple sclerosis following autologous stem cell transplantation.
Dahkki: Armstrong, R, et al.
Almmustuhtton: (2010)

Comparative Effects of Vitamin D Supplementation on Oxidative Stress in Relapsing–Remitting Multiple Sclerosis
Dahkki: Martyna Lis, et al.
Almmustuhtton: (2024-12-01)

Decrease of Mutual Information in Brain Electrical Activity of Patients with Relapsing-Remitting Multiple Sclerosis
Dahkki: Bruno Lenne, et al.
Almmustuhtton: (2013-01-01)

3 Managing disease activity during treatment with natalizumab in relapsing-remitting multiple sclerosis
Dahkki: Nevin John, et al.
Almmustuhtton: (2024-08-01)

Can Vitamin D Supplementation Improve Inflammation in Relapsing-Remitting Multiple Sclerosis Patients?
Dahkki: Martyna Lis, et al.
Almmustuhtton: (2024-07-01)

A pilot study of monocytes in relapsing remitting multiple sclerosis: Correlation with disease activity
Dahkki: Sara I Taha, et al.
Almmustuhtton: (2024-07-01)